chronic immune thrombocytopenic purpura Prospective phase I/II study of rituximab in childhood and adolescent

[1]  J. Bussel,et al.  Chronic immune thrombocytopenic purpura in children: assessment of rituximab treatment. , 2005, The Journal of pediatrics.

[2]  J. Ware,et al.  Applied Longitudinal Analysis , 2004 .

[3]  J. Leonard,et al.  The efficacy and safety of B‐cell depletion with anti‐CD20 monoclonal antibody in adults with chronic immune thrombocytopenic purpura , 2004, British journal of haematology.

[4]  T. Kühne,et al.  A prospective comparative study of 2540 infants and children with newly diagnosed idiopathic thrombocytopenic purpura (ITP) from the Intercontinental Childhood ITP Study Group. , 2003, The Journal of pediatrics.

[5]  R. Ware,et al.  Successful use of anti-CD20 (rituximab) in severe, life-threatening childhood immune thrombocytopenic purpura. , 2003, The Journal of pediatrics.

[6]  G. Buchanan,et al.  Grading of hemorrhage in children with idiopathic thrombocytopenic purpura. , 2002, The Journal of pediatrics.

[7]  U. Germing,et al.  Treatment of relapsed idiopathic thrombocytopenic purpura with the anti‐CD20 monoclonal antibody rituximab: a pilot study , 2002, European journal of haematology.

[8]  S. Amadori,et al.  Variable patterns of response to rituximab treatment in adults with chronic idiopathic thrombocytopenic purpura. , 2002, Blood.

[9]  S. Amadori,et al.  Rituximab chimeric anti-CD20 monoclonal antibody treatment for adults with chronic idiopathic thrombocytopenic purpura. , 2001, Blood.

[10]  J. Gutheil,et al.  A pilot study of the anti-CD20 monoclonal antibody rituximab in patients with refractory immune thrombocytopenia. , 2000, Seminars in oncology.

[11]  R. Levy,et al.  Rituximab chimeric anti-CD20 monoclonal antibody therapy for relapsed indolent lymphoma: half of patients respond to a four-dose treatment program. , 1998, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[12]  Y. Ravindranath,et al.  The spectrum of Evans’ syndrome , 1997, Archives of disease in childhood.

[13]  T. Taube,et al.  Effect of a single dose of rituximab in chronic immune thrombocytopenic purpura in childhood. , 2005, Haematologica.

[14]  R. Fanin,et al.  B-cell depletion with rituximab as treatment for immune hemolytic anemia and chronic thrombocytopenia. , 2002, Haematologica.

[15]  I Royston,et al.  IDEC-C2B8 (Rituximab) anti-CD20 monoclonal antibody therapy in patients with relapsed low-grade non-Hodgkin's lymphoma. , 1997, Blood.

[16]  D. Czerwinski,et al.  Phase I clinical trial using escalating single-dose infusion of chimeric anti-CD20 monoclonal antibody (IDEC-C2B8) in patients with recurrent B-cell lymphoma. , 1994, Blood.